Speaker Profile
Thomas Schirrmann

Thomas Schirrmann PhD

Immunology and Microbiology
Braunschweig, Lower Saxony, Germany

Connect with the speaker?

Thomas Schirrmann received his Ph.D. in immunology for his work in adoptive cellular immune therapy with chimeric antigen receptor (CAR) Natural Killer (NK) cells from the Humboldt University and worked as a scientist and research group leader in research institutions such as Max-Delbrueck-Center of Molecular Medicine (MDC), Charite Hospital in Berlin and the University of Braunschweig. In over 20 years of his research, he gained broad interdisciplinary expertise in recombinant antibody technologies, protein engineering, and expression, bi-and multi-specific antibodies, fusion proteins, gene-modified immune cells, and immunotherapies. Thomas is the author of more than 70 research articles and the inventor of several patents. He is the Co-founder and CEO of YUMAB a fast-growing biotech company. Thomas received prizes for his outstanding work in translating science into commercialization. Currently, Thomas also acts as CEO of two YUMAB spin-offs, YUMAB, Inc. (USA; founded 2017) and CORAT Therapeutics GmbH (Germany; founded 2020).
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)